Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology

Treating and Managing LAM

At a Glance

The primary treatment for Lymphangioleiomyomatosis (LAM) is sirolimus, a medication that stabilizes lung function and slows disease progression. Patients should avoid estrogen, which fuels LAM growth. For severe, progressive cases, lung transplantation is a highly successful option.

Managing LAM has shifted from reacting to symptoms to proactively stabilizing the disease. Today, the primary goal of treatment is to protect your lung function and maintain your quality of life through a combination of targeted medication and lifestyle adjustments [1][2].

The Standard of Care: Sirolimus

Sirolimus (brand name Rapamune) is the primary medication used to treat LAM [3]. It belongs to a class of drugs called mTOR inhibitors. As we discussed in the Biology of LAM section, it acts as an “artificial brake” for the overactive mTOR engine in LAM cells [4].

The landmark MILES trial proved that sirolimus can stop the decline of lung function, specifically measured by FEV1 (the amount of air you can force out of your lungs in one second) and DLCO (how well your lungs transfer oxygen to your blood) [5][1].

When is Treatment Started?

Not every woman with LAM needs to start sirolimus immediately upon diagnosis. According to the ATS/JRS guidelines, doctors generally consider starting sirolimus if you meet any of the following criteria:

  • Lung Function Impairment: Typically when your FEV1 falls below 70% of what is predicted for your age and height [6].
  • Rapid Decline: If your lung function tests show a significant drop over a short period [7].
  • Lymphatic Issues: If you have symptomatic chylothorax (milky fluid buildup in the chest) or other significant lymphatic masses [6][8].

Managing Side Effects and Risks

While sirolimus is generally well-tolerated, it does have common side effects that your doctor will monitor:

  • Immunosuppression: Sirolimus works by suppressing your immune system. This means you are at an increased risk of infections [9]. You should monitor for fevers, practice excellent hand hygiene, and contact your doctor if you show signs of illness.
  • Severe Wound Healing Delays: Sirolimus significantly impairs your body’s ability to heal wounds [10]. You must inform any surgical or dental team that you are on this medication, as the drug typically needs to be paused before and after surgeries, invasive procedures, or tooth extractions to prevent major wound complications.
  • Mouth Sores (Mucositis): Small, painful sores in the mouth are common [11].
  • Cycle Changes: Many women experience irregular menstrual periods while on the drug [9].
  • Cholesterol: It can sometimes raise your cholesterol or triglyceride levels [6].

Doctors often use “low-dose” regimens or adjust your dose based on a blood test that measures the trough level (the amount of drug in your system) to find the right balance between effectiveness and side effects [12][13].

The Role of Estrogen

Research shows that estrogen acts as a fuel for LAM cell growth [14]. Because of this, the current medical consensus is to avoid medications that contain estrogen, such as:

  • Combined oral contraceptive pills (birth control) [3].
  • Traditional hormone replacement therapy (HRT) for menopause [3].

(Note: Patients often worry about dietary sources of estrogen, like soy. Current evidence suggests that dietary phytoestrogens in normal amounts are safe and you do not need to panic about eating soy [3].)

If you need birth control or help with menopausal symptoms, talk to your specialist about progestin-only options or non-hormonal alternatives that are safer for LAM patients.

Advanced Care: Lung Transplantation

While many women with LAM never require a transplant, for those whose LAM continues to progress despite treatment, lung transplantation is a highly successful option [15].

  • When to consider it: Referral for a transplant evaluation is usually discussed when a patient has severe shortness of breath at rest, requires supplemental oxygen, or has an FEV1 that has dropped significantly (often below 30%) [16][7].
  • Outcomes: LAM patients generally have excellent outcomes following a lung transplant, with survival rates that are often better than those for other chronic lung diseases [17][18]. While LAM cells can occasionally reappear in the new lungs, it rarely impacts the success of the transplant [19][20].
Treatment Goal Approach Benefit
Stabilize Lung Function Sirolimus (mTOR inhibitor) [5] Slows or stops FEV1/DLCO decline [1]
Hormone Control Avoid Estrogen [3] Removes “fuel” for LAM cell growth [14]
End-Stage Relief Lung Transplantation [15] Significantly improves survival and QoL [21]

Common questions in this guide

When should I start taking sirolimus for LAM?
Doctors typically consider starting sirolimus if your lung function (FEV1) drops below 70% of what is expected, if your breathing tests show a rapid decline, or if you develop a milky fluid buildup in your chest. Not everyone needs to start medication immediately upon diagnosis.
Can I take birth control pills if I have LAM?
You should avoid birth control pills that contain estrogen, as research shows estrogen acts as a fuel for LAM cell growth. Talk to your specialist about progestin-only options or non-hormonal birth control alternatives.
What are the side effects of taking sirolimus?
Common side effects include mouth sores, irregular menstrual periods, increased cholesterol, and a higher risk of infections due to a suppressed immune system. Sirolimus also severely delays wound healing, so it must be paused before surgeries or dental work.
Will I need a lung transplant for LAM?
Many women with LAM never need a lung transplant. However, if your lung function drops significantly, you require supplemental oxygen, or you have severe shortness of breath at rest, a lung transplant is a highly successful and common option.
How do doctors monitor if my LAM is getting worse?
Doctors primarily track disease progression using breathing tests like FEV1, which measures the amount of air you can forcefully exhale in one second, and DLCO, which measures how well oxygen transfers from your lungs into your blood.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for sirolimus now, or should we continue to monitor my lung function?
  2. 2.Based on my current FEV1 and DLCO, how quickly is my disease progressing?
  3. 3.Are the birth control or hormonal medications I am taking safe for someone with LAM?
  4. 4.If I start sirolimus, how will we monitor the drug levels in my blood to prevent side effects?
  5. 5.At what point in my lung function decline should we begin discussing a lung transplant evaluation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Determinants of Progression and Mortality in Lymphangioleiomyomatosis.

    Xu W, Yang C, Cheng C, et al.

    Chest 2023; (164(1)):137-148 doi:10.1016/j.chest.2023.02.026.

    PMID: 36801466
  2. 2

    Clinical and Functional Outcomes Associated with Quality of Life in Patients with Lymphangioleiomyomatosis: A Cross-Sectional Study.

    Queiroz DS, da Silva CCBM, Oliveira MR, et al.

    Lung 2024; (202(6)):757-765 doi:10.1007/s00408-024-00751-w.

    PMID: 39402376
  3. 3

    Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

    McCormack FX, Gupta N, Finlay GR, et al.

    American journal of respiratory and critical care medicine 2016; (194(6)):748-61 doi:10.1164/rccm.201607-1384ST.

    PMID: 27628078
  4. 4

    CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.

    Evans JF, Obraztsova K, Lin SM, Krymskaya VP

    International journal of molecular sciences 2021; (22(5)) doi:10.3390/ijms22052233.

    PMID: 33668092
  5. 5

    A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.

    Argula RG, Kokosi M, Lo P, et al.

    Annals of the American Thoracic Society 2016; (13(3)):342-9 doi:10.1513/AnnalsATS.201509-631OC.

    PMID: 26799509
  6. 6

    Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.

    Zhan Y, Shen L, Xu W, et al.

    Orphanet journal of rare diseases 2018; (13(1)):34 doi:10.1186/s13023-018-0775-9.

    PMID: 29458386
  7. 7

    Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.

    Chang S, Choi JS, Leem AY, et al.

    Scientific reports 2022; (12(1)):8260 doi:10.1038/s41598-022-12314-1.

    PMID: 35585116
  8. 8

    SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.

    Hecimovic A, Jakopovic M, Pavlisa G, et al.

    Lymphology 2015; (48(2)):97-102.

    PMID: 26714374
  9. 9

    Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.

    Takada T, Mikami A, Kitamura N, et al.

    Annals of the American Thoracic Society 2016; (13(11)):1912-1922 doi:10.1513/AnnalsATS.201605-335OC.

    PMID: 27513278
  10. 10

    Stepwise Incremental Dose Schedule of Sirolimus Is Successfully Tolerated by a Patient With Lymphangioleiomyomatosis Who Was Initially Allergic to mTOR Inhibitors.

    Seyama K, Komiyama E, Tsuchihashi H, et al.

    Cureus 2024; (16(4)):e58805 doi:10.7759/cureus.58805.

    PMID: 38784348
  11. 11

    Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series.

    Zhou L, Ouyang R, Luo H, et al.

    Orphanet journal of rare diseases 2018; (13(1)):168 doi:10.1186/s13023-018-0915-2.

    PMID: 30241551
  12. 12

    Low-dose sirolimus in retroperitoneal lymphangioleiomyomas.

    Ussavarungsi K, Laroia AT, Burger CD

    Lung India : official organ of Indian Chest Society 2019; (36(4)):349-352 doi:10.4103/lungindia.lungindia_433_18.

    PMID: 31290423
  13. 13

    Application of sirolimus in an infant presenting with a life-threatening lymphatic malformation of the head and neck: a case report.

    Yu S, Guo X

    Frontiers in pediatrics 2025; (13()):1587330 doi:10.3389/fped.2025.1587330.

    PMID: 40342900
  14. 14

    Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet.

    Gibbons E, Minor BMN, Hammes SR

    Endocrine-related cancer 2023; (30(9)).

    PMID: 37410387
  15. 15

    Lung Transplantation for Lymphangioleiomyomatosis in Japan.

    Ando K, Okada Y, Akiba M, et al.

    PloS one 2016; (11(1)):e0146749 doi:10.1371/journal.pone.0146749.

    PMID: 26771878
  16. 16

    COVID-19 in a patient with sporadic lymphangioleiomyomatosis awaiting lung transplantation.

    Noda Y, Shiroyama T, Amiya S, et al.

    Respiratory medicine case reports 2021; (34()):101505 doi:10.1016/j.rmcr.2021.101505.

    PMID: 34493971
  17. 17

    Lung transplantation for lymphangioleiomyomatosis.

    Warrior K, Dilling DF

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; (42(1)):40-52 doi:10.1016/j.healun.2022.09.021.

    PMID: 36334961
  18. 18

    Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.

    Ussavarungsi K, Hu X, Scott JP, et al.

    Respiratory medicine 2015; (109(10)):1354-9.

    PMID: 26321137
  19. 19

    Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation.

    Zaki KS, Aryan Z, Mehta AC, et al.

    World journal of transplantation 2016; (6(1)):249-54 doi:10.5500/wjt.v6.i1.249.

    PMID: 27011924
  20. 20

    Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan.

    Oishi H, Watanabe T, Matsuda Y, et al.

    Surgery today 2018; (48(10)):944-950 doi:10.1007/s00595-018-1678-z.

    PMID: 29808303
  21. 21

    Correlation between the native lung volume change and postoperative pulmonary function after single lung transplantation for lymphangioleiomyomatosis: Evaluation of lung volume by three-dimensional computed tomography volumetry.

    Suzuki H, Oishi H, Noda M, et al.

    PloS one 2019; (14(2)):e0210975 doi:10.1371/journal.pone.0210975.

    PMID: 30742625

This page provides educational information about Lymphangioleiomyomatosis (LAM) treatments, including sirolimus. It is for informational purposes only and does not replace professional medical advice from your pulmonologist or transplant team.

Get notified when new evidence is published on Lymphangioleiomyomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.